255 related articles for article (PubMed ID: 38069252)
1. Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies.
Nath SC; Menendez L; Friedrich Ben-Nun I
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069252
[TBL] [Abstract][Full Text] [Related]
2. Role of epigenetics in cellular reprogramming; from iPSCs to disease modeling and cell therapy.
Li Y; Darabi R
J Cell Biochem; 2022 Feb; 123(2):147-154. PubMed ID: 34668236
[TBL] [Abstract][Full Text] [Related]
3. Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.
Chhabra A
Stem Cell Rev Rep; 2017 Dec; 13(6):757-773. PubMed ID: 28918520
[TBL] [Abstract][Full Text] [Related]
4. Overcoming barriers to the clinical utilization of iPSCs: reprogramming efficiency, safety and quality.
Cao S; Loh K; Pei Y; Zhang W; Han J
Protein Cell; 2012 Nov; 3(11):834-45. PubMed ID: 23073833
[TBL] [Abstract][Full Text] [Related]
5. Induced pluripotent stem cells: fundamentals and applications of the reprogramming process and its ramifications on regenerative medicine.
Walia B; Satija N; Tripathi RP; Gangenahalli GU
Stem Cell Rev Rep; 2012 Mar; 8(1):100-15. PubMed ID: 21671061
[TBL] [Abstract][Full Text] [Related]
6. Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming.
Rony IK; Baten A; Bloomfield JA; Islam ME; Billah MM; Islam KD
Cell Prolif; 2015 Apr; 48(2):140-56. PubMed ID: 25643745
[TBL] [Abstract][Full Text] [Related]
7. Effects of Integrating and Non-Integrating Reprogramming Methods on Copy Number Variation and Genomic Stability of Human Induced Pluripotent Stem Cells.
Kang X; Yu Q; Huang Y; Song B; Chen Y; Gao X; He W; Sun X; Fan Y
PLoS One; 2015; 10(7):e0131128. PubMed ID: 26131765
[TBL] [Abstract][Full Text] [Related]
8. Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine.
Poetsch MS; Strano A; Guan K
Stem Cells; 2022 Jun; 40(6):546-555. PubMed ID: 35291013
[TBL] [Abstract][Full Text] [Related]
9. Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34
Okumura T; Horie Y; Lai CY; Lin HT; Shoda H; Natsumoto B; Fujio K; Kumaki E; Okano T; Ono S; Tanita K; Morio T; Kanegane H; Hasegawa H; Mizoguchi F; Kawahata K; Kohsaka H; Moritake H; Nunoi H; Waki H; Tamaru SI; Sasako T; Yamauchi T; Kadowaki T; Tanaka H; Kitanaka S; Nishimura K; Ohtaka M; Nakanishi M; Otsu M
Stem Cell Res Ther; 2019 Jun; 10(1):185. PubMed ID: 31234949
[TBL] [Abstract][Full Text] [Related]
10. Overcoming the challenges of scalable iPSC generation in translation medicine.
Liu DH; Tseng HC; Lee MS; Chiou GY; Wang CT; Lin YY; Lai WY; Liu YH; Wang CY; Lee CY; Kao CL; Chen CF; Chien Y
J Chin Med Assoc; 2024 Feb; 87(2):163-170. PubMed ID: 38132887
[TBL] [Abstract][Full Text] [Related]
11. Progress in the reprogramming of somatic cells.
Ma T; Xie M; Laurent T; Ding S
Circ Res; 2013 Feb; 112(3):562-74. PubMed ID: 23371904
[TBL] [Abstract][Full Text] [Related]
12. Age Is Relative-Impact of Donor Age on Induced Pluripotent Stem Cell-Derived Cell Functionality.
Strässler ET; Aalto-Setälä K; Kiamehr M; Landmesser U; Kränkel N
Front Cardiovasc Med; 2018; 5():4. PubMed ID: 29423397
[TBL] [Abstract][Full Text] [Related]
13. Cell type of origin influences iPSC generation and differentiation to cells of the hematoendothelial lineage.
Phetfong J; Supokawej A; Wattanapanitch M; Kheolamai P; U-Pratya Y; Issaragrisil S
Cell Tissue Res; 2016 Jul; 365(1):101-12. PubMed ID: 26893154
[TBL] [Abstract][Full Text] [Related]
14. Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells.
Sommer CA; Christodoulou C; Gianotti-Sommer A; Shen SS; Sailaja BS; Hezroni H; Spira A; Meshorer E; Kotton DN; Mostoslavsky G
PLoS One; 2012; 7(12):e51711. PubMed ID: 23272148
[TBL] [Abstract][Full Text] [Related]
15. Human-Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions.
Rivera T; Zhao Y; Ni Y; Wang J
Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e117. PubMed ID: 32649060
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial regulation in human pluripotent stem cells during reprogramming and β cell differentiation.
Jasra IT; Cuesta-Gomez N; Verhoeff K; Marfil-Garza BA; Dadheech N; Shapiro AMJ
Front Endocrinol (Lausanne); 2023; 14():1236472. PubMed ID: 37929027
[TBL] [Abstract][Full Text] [Related]
17. Induced pluripotent stem cells reprogramming: Epigenetics and applications in the regenerative medicine.
Gomes KM; Costa IC; Santos JF; Dourado PM; Forni MF; Ferreira JC
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):180-189. PubMed ID: 28355380
[TBL] [Abstract][Full Text] [Related]
18. Biomaterial aided differentiation and maturation of induced pluripotent stem cells.
Velmurugan BK; Bharathi Priya L; Poornima P; Lee LJ; Baskaran R
J Cell Physiol; 2019 Jun; 234(6):8443-8454. PubMed ID: 30565686
[TBL] [Abstract][Full Text] [Related]
19. A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells.
Moad M; Pal D; Hepburn AC; Williamson SC; Wilson L; Lako M; Armstrong L; Hayward SW; Franco OE; Cates JM; Fordham SE; Przyborski S; Carr-Wilkinson J; Robson CN; Heer R
Eur Urol; 2013 Nov; 64(5):753-61. PubMed ID: 23582880
[TBL] [Abstract][Full Text] [Related]
20. The transcription factor code in iPSC reprogramming.
Deng W; Jacobson EC; Collier AJ; Plath K
Curr Opin Genet Dev; 2021 Oct; 70():89-96. PubMed ID: 34246082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
